News
![Affluent Medical will attend to the 2022 London LSX World Congress](https://www.affluentmedical.com/wp-content/uploads/2022/04/londres-5.jpg)
Affluent Medical will attend to the 2022 London LSX World Congress
May 10 & 11, 2022
Speakers: Michel Finance, President and François Laborde Chief Medical Officer
![Affluent Medical will held a presentation during the Innovation Summit Dublin 2022](https://www.affluentmedical.com/wp-content/uploads/2022/04/dublin2022-1.jpg)
Affluent Medical will held a presentation
during the Innovation Summit Dublin 2022
On April 27, 2022 at 3:25 pm
Speakers: Michel Finance, President and François Laborde Chief Medical Officer
![Appointment of a new independent board member to the Affluent Medical Board of Directors](https://www.affluentmedical.com/wp-content/uploads/2022/01/post25nov2022-2.jpg)
Appointment of a new independent board member to the Affluent Medical Board of Directors
Soad El Ghazouani has over 25 years of global experience in the medical device industry with extensive knowledge of the pan-European and North American markets.
![Successful first post-operative adjustment of KaliosTM mitral ring](https://www.affluentmedical.com/wp-content/uploads/2021/11/post10nov2021-1.jpg)
Successful first post-operative adjustment of KaliosTM mitral ring
Prof. Alberto Albertini (GMV Maria Cecilia Hospital de Cotignola, Italy) successfully performed the percutaneous adjustment of the original KaliosTM annuloplasty ring 11 months after its implantation following a recurrence of severe mitral insufficiency.
![IPO launch on Euronext Paris](https://www.affluentmedical.com/wp-content/uploads/2021/07/visuels_news_finance_generique.jpg)
IPO launch on Euronext Paris
AFFLUENT MEDICAL launches its IPO on the regulated Euronext Paris market
• Capital increase of approximately €33.0 million, which may be increased to approximately €43.6 million in the event of the full exercise of the extension and over-allotment clause
• Subscription commitments received in the amount of €20 million
• Indicative price range applicable to the Offering: between €7.40 and €9.80 per share
• Subscription period: from 27 May 2021 to 8 June 2021, inclusive, for the French Public Offer (5:00 p.m. for subscriptions over the counter and 8:00 p.m. for internet subscriptions) and until noon on 9 June 2021 for the international offering
![Epygon publication](https://www.affluentmedical.com/wp-content/uploads/2021/07/post2.jpg)
Epygon publication
Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency.
• Preclinical in vivo results published in The Annals of Thoracic Surgery confirm the Epygon mitral valve ability to adapt to the heart while restoring the native-like blood flow.
• Epygon has been designed to replicate the human physiology to allow a better recovery of the left ventricular function minimizing the risk of cardiac insufficiency.
• A first-in-human clinical trial in 15 patients will be initiated in the 2nd semester 2021 and a pivotal study will be initiated in the US and Europe in the 2nd semester 2022.